NEWS: FEBRUARY 2005

-02/25/2005-

FDA approves Roche's Pegasys® for the treatment of Hepatitis C in patients with HIV. To read article click here.

Genetic mutation called G2019S linked to late-onset of Parkinson's disease. To read article click here.

Bruker Daltonics Inc. introduces the new micrOTOF™-Q mass spectrometer. To read article click here.

UCSF launches the Center for Drug Development Science (CDDS) in Washington, DC. To read article click here.

Memory Pharmaceuticals Corp. initiates Phase I clinical trials of MEM 3454 for the treatment of central nervous system disorders. To read article click here.

-02/24/2005-

Researchers determine 3D shape changes in HIV's gp120 protein as key process for cell infection. To read article click here.

Telik Inc. announces 4th Quarter and 2004 year end financial results. To read article click here.

Genzyme Corp. initiates Phase II gene transfer clinical trials of Ad2/HIF-1 alpha for peripheral arterial disease. To read article click here.

DOV Pharmaceutical Inc. initiates Phase I clinical trials of DOV 102,677 for treatment of depression. To read article click here.

Researchers identify second gene mutation responsible for resistance of gefitinib (Iressa) in non-small-cell lung cancer (NSCLC). To read article click here.

Symyx Technologies Inc. to acquire Synthematix Inc. To read article click here.

Pfizer Inc. to acquire Idun Pharmaceuticals Inc. To read article click here.

-02/23/2005-

Press Release: Frost & Sullivan's new report: Emerging Technologies in Lab-on-a-Chip: Microfluidics and µTAS. To read press release click here.

Prolexys Pharmaceuticals Inc. licences anti-tumor compounds from MIT. To read article click here.

-02/21/2005-

Novartis to acquire Hexal AG and Eon Labs for about $8.3 billion. To read article click here.

Millennium Pharmaceuticals Inc. reports results of Phase I clinical trials of MLN2704 for advanced hormone-refractory prostate cancer. To read article click here.

Cyclacel Group receives US Patent for novel series of pyrimidine small-molecule CDK inhibitors. To read article click here.

Schering-Plough completes the acquisition of NeoGenesis Pharmaceuticals. To read article click here.

-02/18/2005-

FDA approves Medicis Pharmaceutical Corp.'s drug Ammonul for urea cycle disorder treatment. To read article click here.

Spectrum Pharmaceuticals Inc. acquires rights from Chicago Labs Inc. for endothelinB agonists for the treatment of cancer. To read article click here.

-02/17/2005-

Telik Inc. to release its quarterly conference call on Thursday, February 24, 2005. To read article click here.

Telik Inc. will present an update at the BIO CEO and Investor Conference on Wednesday, February 23, 2005. To read article click here.

Atrium Biotechnologies Inc. goes IPO. To read article click here.

Dendreon Corporation posts postive results of Phase III clinical trials of Provenge® for prostate cancer. To read article click here.

-02/16/2005-

Teva Pharmaceutical Industries Ltd. and Gamida-Cell Ltd. to form joint venture to develop and commercialize StemEx® for leukemia and lymphoma treatment. To read article click here.

DOR BioPharma Inc. begins research program for small molecule drugs against Botulinum toxin exposure. To read article click here.

-02/15/2005-

Ivax Corp. to acquire Phoenix Scientific Inc. for $271.9 million. To read article click here.

Critical Therapeutics Inc. initiates Phase II clinical trials of CTI-01 for ischemia and reperfusion injury treatment. To read article click here.

Penwest Pharmaceuticals Co.'s CEO resigns. To read article click here.

Seattle Genetics Inc. and CuraGen Corporation expand antibody-drug conjugate collaboration. To read article click here.

Vertex Pharmaceuticals Inc. and Avalon Pharmaceuticals Inc. form alliance for the development of anticancer candidate VX-944. To read article click here.

-02/14/2005-

Renovis Inc. initiates Phase Ia clinical trials of REN-850 for multiple sclerosis. To read article click here.

Depomed Inc. begins Phase II clinical trials of Gabapentin for herpes zoster (shingles) infection. To read article click here.

Isis Pharmaceuticals Inc. licenses anti-cancer antisense thymidylate synthase inhibitor drug to Sarissa Inc. To read article click here.

-02/04/2005-

Clinical trials of Novartis AG's painkiller Prexige points to risk of heart attack, stroke and death. To read article click here.

Novavax Inc. receives $1.1 million grant to develop a SARS vaccine. To read article click here.

Repligen Corp.'s clinical trials of secretin in refractory schizophrenia failed to show statistically significant improvement. To read article click here.

ViroLogic and GlaxoSmithKline form HIV drug discovery alliance. To read article click here.

Anadys Pharma inititates Phase I clinical trials of ANA975 for hepatitis C. To read article click here.

-02/03/2005-

GlaxoSmithKline wins cervical cancer patent dispute with Merck. To read article click here.

Elan Corporation receives Japanese Patent Number 36020546 for its proprietary NanoCrystal™ Technology. To read article click here.

Vasogen Inc. initiates Phase I clinical trial of VP025 for inflammation. To read article click here.

Kyorin Pharmaceutical Co. completes the acquisition of ActivX Biosciences for $21 million. To read article click here.

Stat5 protein inhibits spread of breast cancer cells. To read article click here.

-02/02/2005-

Biotech Progen Industries Ltd to initate Phase II clinical trials of PI-88 for advanced melanoma. To read article click here.

NexMed Inc. initiates Phase I clinical trials of NM10060 for nail fungal infection. To read article click here.

Icoria and DuPont Crop Protection form research collaboration. To read article click here.

Clinical trials of Pfizer Inc.'s U11248 for gastrointestinal stromal tumor treatment found to be effective. To read article click here.

-02/01/2005-

FDA places StemCells Inc.'s clinical trials on hold. To read article click here.

US government add viruses to list of causes of cancer. To read article click here.

CuraGen Corporation and TopoTarget A/S move small molecule histone deacetylase inhibitor PXD101 to Phase II clinical trials for advanced multiple myeloma. To read article click here.